3. Limfomska šola – program/ 3rd school of malignant lymphomas

Onkološki inštitut Ljubljana, Ljubljana, Slovenia

Thursday 19th October and Friday 20th October 2023

PROGRAMME

Thursday 19.10.2023

Chairman: prof. Veronika Kloboves Prevodnik, dr. Gorana Gašljević

9.00 – 9.10: Opening speach (dr. Gašljević, prof. Kloboves Prevodnik)

9.00 – 9.45: 5th WHO classification of Lymphoid malignanices (prof. Andrew Wotherspoon, The Royal Marsden, England)

9.45 –10.00: A Proposal for the Performance, Classification, and Reporting of Lymph Node Fine-Needle Aspiration Cytopathology: The Sydney System (prof. Kloboves Prevodnik)

10.00 – 10.40: Treatment of ALL and flow cytometric analyses of MRD (prof. Michael Dworzak, St. Anna Kinderspital, Vienna, Austria)

10.40 – 11.00: Treatment of ALL – our centre experience (assist. prof.. Matevž Škerget, Dept. Of Hematology, University Clinical Centre Ljubljana, Slovenia)

11.00 – 11.30: Coffee break

11.30 – 12.30: Pathology and cytopathology workshops part I

Case1. Gazić Barbara, Klopčič Ulrika: T-cell lymphoblastic lymphoma vs thymoma in effusion as well as in small biopsies

Case 2. Gazić Barbara, Klopčič Ulrika: Nodal B-cell lymphoblastic lymphoma and its pitfalls in cytopathology

Case 3: Grčar-Kuzmanov Biljana, Kloboves Prevodnik Veronika: Classical Hodgkin lymphoma vs Primary mediastinal large B-cell lymphoma

Case 4. Grčar-Kuzmanov Biljana, Rode Aleš: Burkitt lymphoma vs diffuse large B-cell lymphoma

12.30 - 13.15: Lunch

13.15-14.15: Pathology and cytopathology workshops part II

Case 5. Gašljević Gorana, Jeričević Anja: Nodular lymphocyte predominant Hodgkin lymphoma vs T-cell/histiocyte rich large B-cell lymphoma

Case 6. Gašljević Gorana, Jeričevič Anja: Classical Hodgkins lymphoma vs Nodular

lymphocyte predominant Hodgkin lymphoma

Case 7. Wotherspoon Andrew: Criteria for transformation of MZL into DLBCL (

Case 8. Car Milan, Rode Aleš: PEL versus PAL

Flow cytometry workshop in flow lab (3hours, parallel to patho workshop)

Friday 20.10.2023

Chairman: prof. Barbara Jezeršek Novaković, assist. prof. Lučka Boltežar

9.00 – 09.30: Molecular pathogenesis of DLBCL (prof. Andrew Wotherspoon, The Royal Marsden, England)

09.30 – 10.00: Risk stratification in DLBCL - clinical prognostic factors, molecular prognostic factors (prof. Thomas Melchardt, SALK, Paracelsus Medical University Salzburg, Austria)

10.00 – 10.15: First line treatment of DLBCL in regard to molecular pathogenesis (Milica Miljković, Institute of Oncology Ljubljana, Slovenia)

10.15 – 10.45: Coffee break

10.45 – 11.05: Favorable and unfavorable subtypes of DLBCL (dr. Gorana Gašljević, Urška Rugelj, Institute of Oncology Ljubljana, Slovenia)

11.05 – 11.25: Treatment of R&R DLBCL in regard to molecular pathogenesis (prof. Barbara Jezeršek Novaković, Institute of Oncology Ljubljana, Slovenia)

11.25 – 11.45: Treatment of R&R DLBCL – our centre experience (Maria Cristina Pirosa, Institute of Southern Switzerland, Switzerland)

11.45 – 12.05: Treatment of R&R DLBCL – our centre experience (assist. prof. Lučka Boltežar, Institute of Oncology Ljubljana, Slovenia)

12.05 – 12.30: Discussion

12.30 – 13.30: Lunch

13.30 – 15.00: Difficult cases presentations and discussion (assist. prof. Lučka Boltežar, Maria Cristina Pirosa, Institute of Southern Switzerland, Switzerland, Aleš C. Mihelač, Tina Zupančič, Anja Žižek, Matej Panjan, Institute of Oncology Ljubljana, Slovenia)